VTRS · Company research
Viatris Inc. Common Stock (VTRS): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
35records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| VTRS,PNW,EA,CCL | stock prices | quote comparison - Yahoo Finance UK | VTRS,PNW,EA,CCL | stock prices | quote comparison Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 19, 2026 | neutral | 0 | 0.6 |
| Presbyopia Approval Might Change The Case For Investing In Viatris Stock (VTRS) - Simply Wall Street | Presbyopia Approval Might Change The Case For Investing In Viatris Stock (VTRS) Simply Wall Street | View source ↗ | Simply Wall Street | Oct 18, 2026 | neutral | 0 | 0.6 |
| Viatris (VTRS) Wins FDA Approval For RYZUMVI, Is The Upside Already Priced In? - Simply Wall Street | Viatris (VTRS) Wins FDA Approval For RYZUMVI, Is The Upside Already Priced In? Simply Wall Street | View source ↗ | Simply Wall Street | Oct 17, 2026 | neutral | 0 | 0.6 |
| The FDA approves Viatris eye drops for adults who struggle to focus up close - Stock Titan | The FDA approves Viatris eye drops for adults who struggle to focus up close Stock Titan | View source ↗ | Stock Titan | Oct 16, 2026 | neutral | 0 | 0.6 |
| Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia | Opus Genetics announced FDA approval of phentolamine ophthalmic solution 0.75% (RYZUMVI®) for treating presbyopia in adults, expanding its previous indication for pharmacologically-induced mydriasis. The approval was supported by positive Phase 3 VEGA-2 and VEGA-3 trial results and will trigger a milestone payment from commercial partner Viatris Inc. Presbyopia affects approximately 90% of U.S. adults over 45, and the drug offers a non-invasive treatment option. | View source ↗ | GlobeNewswire Inc. | Oct 16, 2026 | bullish | 1 | 1 |
| Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia | Opus Genetics announced FDA approval of phentolamine ophthalmic solution 0.75% (RYZUMVI®) for treating presbyopia in adults, expanding its previous indication for pharmacologically-induced mydriasis. The approval was supported by positive Phase 3 VEGA-2 and VEGA-3 trial results and will trigger a milestone payment from commercial partner Viatris Inc. Presbyopia affects approximately 90% of U.S. adults over 45, and the drug offers a non-invasive treatment option. | View source ↗ | GlobeNewswire Inc. | Oct 16, 2026 | bullish | 1 | 1 |
| Viatris Inc (VTRS) Shares Surge 4.5% -- What GF Score of 63 Tells Investors - GuruFocus | Viatris Inc (VTRS) Shares Surge 4.5% -- What GF Score of 63 Tells Investors GuruFocus | View source ↗ | GuruFocus | Oct 15, 2026 | neutral | 0 | 0.6 |
| SA analyst upgrades/downgrades: META, VTRS, MRVL, COKE (META:NASDAQ) - Seeking Alpha | SA analyst upgrades/downgrades: META, VTRS, MRVL, COKE (META:NASDAQ) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 13, 2026 | neutral | 0 | 0.6 |
| Viatris: Is The Pacira Deal A Game Changer? (Rating Upgrade) (NASDAQ:VTRS) - Seeking Alpha | Viatris: Is The Pacira Deal A Game Changer? (Rating Upgrade) (NASDAQ:VTRS) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 12, 2026 | neutral | 0 | 0.6 |
| Viatris: Improved Confidence Drives M&A Action Again (NASDAQ:VTRS) - Seeking Alpha | Viatris: Improved Confidence Drives M&A Action Again (NASDAQ:VTRS) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 12, 2026 | neutral | 0 | 0.6 |
| Viatris (NasdaqGS:VTRS) Stock Forecast & Analyst Predictions - Simply Wall Street | Viatris (NasdaqGS:VTRS) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 11, 2026 | neutral | 0 | 0.6 |
| Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio | Viatris (VTRS) has agreed to acquire Pacira BioSciences (PCRX) for $1.65 billion in cash at $36.50 per share, expected to close by end of 2026. The acquisition adds two marketed pain therapies (Exparel and Zilretta) generating $350.5 million in H1 2026 sales, plus a mid-stage gene therapy candidate (PCRX-201) for knee osteoarthritis. The deal is expected to be immediately accretive to Viatris' financial metrics and strengthen its non-opioid pain management portfolio. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio | Viatris (VTRS) has agreed to acquire Pacira BioSciences (PCRX) for $1.65 billion in cash at $36.50 per share, expected to close by end of 2026. The acquisition adds two marketed pain therapies (Exparel and Zilretta) generating $350.5 million in H1 2026 sales, plus a mid-stage gene therapy candidate (PCRX-201) for knee osteoarthritis. The deal is expected to be immediately accretive to Viatris' financial metrics and strengthen its non-opioid pain management portfolio. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| Viatris to Acquire Pacira, Expanding Non-Opioid Portfolio - The Globe and Mail | Viatris to Acquire Pacira, Expanding Non-Opioid Portfolio The Globe and Mail | View source ↗ | The Globe and Mail | Oct 9, 2026 | neutral | 0 | 0.6 |
| Viatris To Acquire Pacira BioSciences - What Investors Should Know (NASDAQ:VTRS) - Seeking Alpha | Viatris To Acquire Pacira BioSciences - What Investors Should Know (NASDAQ:VTRS) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 9, 2026 | neutral | 0 | 0.6 |
| Viatris (VTRS) Buys Pacira As Fair Value Stays In Focus - Yahoo Finance | Viatris (VTRS) Buys Pacira As Fair Value Stays In Focus Yahoo Finance | View source ↗ | Yahoo Finance | Oct 9, 2026 | neutral | 0 | 0.6 |
| Why Pacira BioSciences Skyrocketed Today | Pacira BioSciences surged 44% after announcing its acquisition by Viatris for $36.50 per share, valuing the company at approximately $1.65 billion. The deal represents a 45% premium to the previous closing price and is expected to close by end of 2026. Viatris plans to leverage Pacira's non-opioid pain management products, including Exparel and Zilretta, to strengthen its innovative medicines business. | View source ↗ | The Motley Fool | Oct 8, 2026 | bullish | 0.5 | 1 |
| Why Pacira BioSciences Skyrocketed Today | Pacira BioSciences surged 44% after announcing its acquisition by Viatris for $36.50 per share, valuing the company at approximately $1.65 billion. The deal represents a 45% premium to the previous closing price and is expected to close by end of 2026. Viatris plans to leverage Pacira's non-opioid pain management products, including Exparel and Zilretta, to strengthen its innovative medicines business. | View source ↗ | The Motley Fool | Oct 8, 2026 | bullish | 0.5 | 1 |
| Why Pacira BioSciences Skyrocketed Today | Pacira BioSciences surged 44% after announcing its acquisition by Viatris for $36.50 per share, valuing the company at approximately $1.65 billion. The deal represents a 45% premium to the previous closing price and is expected to close by end of 2026. Viatris plans to leverage Pacira's non-opioid pain management products, including Exparel and Zilretta, to strengthen its innovative medicines business. | View source ↗ | The Motley Fool | Oct 8, 2026 | bullish | 0.5 | 1 |
| Viatris Inc (VTRS) Stock Price, Quote, News & History - Benzinga | Viatris Inc (VTRS) Stock Price, Quote, News & History Benzinga | View source ↗ | Benzinga | Oct 8, 2026 | neutral | 0 | 0.6 |
| VTRS vs. AVTR: Which Stock Is the Better Value Option? | A comparison of two Medical Services sector stocks, Viatris (VTRS) and Avantor (AVTR), both holding a Zacks Rank #2 (Buy) rating. Based on valuation metrics including forward P/E ratio (7.01 vs 19.51), PEG ratio (1.92 vs 11.93), and P/B ratio (1.44 vs 1.9), Viatris emerges as the superior value opportunity with a Value grade of A compared to Avantor's C grade. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.5 | 1 |
| VTRS vs. AVTR: Which Stock Is the Better Value Option? | A comparison of two Medical Services sector stocks, Viatris (VTRS) and Avantor (AVTR), both holding a Zacks Rank #2 (Buy) rating. Based on valuation metrics including forward P/E ratio (7.01 vs 19.51), PEG ratio (1.92 vs 11.93), and P/B ratio (1.44 vs 1.9), Viatris emerges as the superior value opportunity with a Value grade of A compared to Avantor's C grade. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.5 | 1 |
| Should Value Investors Buy Viatris (VTRS) Stock? | Viatris (VTRS) is presented as an attractive value investment opportunity, holding a Zacks Rank #2 (Buy) rating with an 'A' Value grade. The stock demonstrates undervaluation across multiple metrics including a P/B ratio of 0.75 (below industry average of 2.17), P/S ratio of 1.37 (below industry average of 1.54), and P/CF ratio of 5.21 (significantly below industry average of 11.92), suggesting solid cash flow and earnings outlook. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 1 | 1 |
| Should Value Investors Buy Viatris (VTRS) Stock? | Viatris (VTRS) is presented as an attractive value investment opportunity, holding a Zacks Rank #2 (Buy) rating with an 'A' Value grade. The stock demonstrates undervaluation across multiple metrics including a P/B ratio of 0.75 (below industry average of 2.17), P/S ratio of 1.37 (below industry average of 1.54), and P/CF ratio of 5.21 (significantly below industry average of 11.92), suggesting solid cash flow and earnings outlook. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 1 | 1 |
| Should Value Investors Buy Viatris (VTRS) Stock? - Yahoo Finance | Should Value Investors Buy Viatris (VTRS) Stock? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 6, 2026 | neutral | 0 | 0.6 |
| VTRS vs. AVTR: Which Stock Is the Better Value Option? - Yahoo Finance | VTRS vs. AVTR: Which Stock Is the Better Value Option? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 6, 2026 | neutral | 0 | 0.6 |
| Viatris (VTRS) is a Top-Ranked Momentum Stock: Should You Buy? | Zacks Premium offers investment research tools including the Zacks Rank and Style Scores to help investors identify stocks with strong performance potential. The Zacks Rank #1 stocks have averaged +23.86% annual returns since 1988, more than double the S&P 500. The article highlights Viatris (VTRS) as a stock to watch with a #3 Hold rank and VGM Score of A, noting recent upward earnings estimate revisions and positive momentum. | View source ↗ | Zacks Investment Research | Oct 5, 2026 | bullish | 1 | 1 |
| A third-quarter results call is set for 8:30 a.m. ET on Nov. 5, with Viatris executives hosting. - Stock Titan | A third-quarter results call is set for 8:30 a.m. ET on Nov. 5, with Viatris executives hosting. Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| Is WisdomTree U.S. MidCap Dividend ETF (DON) a Strong ETF Right Now? | The WisdomTree U.S. MidCap Dividend ETF (DON) is a smart beta ETF offering exposure to mid-cap dividend-paying stocks with a 0.38% expense ratio and 2.41% dividend yield. With $3.77 billion in assets and 295 holdings, it has delivered 6.93% returns year-to-date with medium risk (beta 0.86). However, cheaper alternatives like Vanguard's VOE (0.05% expense ratio) and iShares' IWS (0.23% expense ratio) offer lower-cost options for similar market exposure. | View source ↗ | Zacks Investment Research | Oct 2, 2026 | bullish | 0.333 | 1 |
| Is WisdomTree U.S. MidCap Dividend ETF (DON) a Strong ETF Right Now? | The WisdomTree U.S. MidCap Dividend ETF (DON) is a smart beta ETF offering exposure to mid-cap dividend-paying stocks with a 0.38% expense ratio and 2.41% dividend yield. With $3.77 billion in assets and 295 holdings, it has delivered 6.93% returns year-to-date with medium risk (beta 0.86). However, cheaper alternatives like Vanguard's VOE (0.05% expense ratio) and iShares' IWS (0.23% expense ratio) offer lower-cost options for similar market exposure. | View source ↗ | Zacks Investment Research | Oct 2, 2026 | bullish | 0.333 | 1 |
| Why Viatris (VTRS) is a Top Value Stock for the Long-Term | Recent economic data shows PCE inflation came in softer than expected while Q2 GDP exceeded expectations. Market attention is now focused on the upcoming Friday employment report. Viatris (VTRS) is highlighted as a stock to watch with a Hold rating and attractive valuation metrics. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | neutral | 0 | 1 |
| Why Viatris (VTRS) is a Top Value Stock for the Long-Term | Recent economic data shows PCE inflation came in softer than expected while Q2 GDP exceeded expectations. Market attention is now focused on the upcoming Friday employment report. Viatris (VTRS) is highlighted as a stock to watch with a Hold rating and attractive valuation metrics. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | neutral | 0 | 1 |
| Is Viatris Stock Outperforming the S&P 500? - Yahoo Finance | Is Viatris Stock Outperforming the S&P 500? Yahoo Finance | View source ↗ | Yahoo Finance | Sep 24, 2026 | neutral | 0 | 0.6 |
| Viatris (VTRS) Stock Sees Modest Fair Value Lift After Q1 Results And Pipeline Progress - Yahoo Finance | Viatris (VTRS) Stock Sees Modest Fair Value Lift After Q1 Results And Pipeline Progress Yahoo Finance | View source ↗ | Yahoo Finance | Aug 9, 2026 | neutral | 0 | 0.6 |
| Viatris (VTRS) Stock And The 58% Undervaluation Debate After A Strong Year Of Returns - Yahoo Finance | Viatris (VTRS) Stock And The 58% Undervaluation Debate After A Strong Year Of Returns Yahoo Finance | View source ↗ | Yahoo Finance | Jun 14, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.